Post

Pint Pharma announces ORLADEYO approval in Mexico for HAE prevention

Pint Pharma has announced that Mexico's Federal Commission for Protection against Health Risks (COFEPRIS) has granted approval for Orladeyo (berotralstat) …

NHS introduces Pfizer’s tafamidis for ATTR-CM treatment

The UK's National Health Service (NHS) has introduced Pfizer's tafamidis for transthyretin amyloidosis cardiomyopathy (ATTR-CM), a rare heart condition characterised …

BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC

Zai Lab has announced that its New Drug Application (NDA) for Augtyro (repotrectinib) has been greenlit by China’s National Medical …

Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy

Japanese pharma company Takeda has signed an exclusive, worldwide option and licence agreement for AC Immune’s amyloid beta-targeting Alzheimer’s disease …

Dupixent set for FDA review in adolescent chronic inflammatory sinus disease

Regeneron and Sanofi could soon be adding another indication to its blockbuster immunology drug Dupixent (dupilumab) after the US Food …